David Gerber, M.D. is a faculty member within the Hematology Oncology Division at UT Southwestern Medical Center. Within the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern, he serves as Associate Director for Clinical Research and as Co-leader of the Experimental Therapeutics Program. Dr. Gerber graduated cum laude from Yale University in New Haven, Connecticut, and his medical degree was obtained through Cornell University Medical College, New York, New York. His internship and residency in Internal Medicine were completed at UT Southwestern Medical Center in Dallas, Texas with his fellowship in medical oncology at Johns Hopkins University School of Medicine in Baltimore, Maryland. Dr. Gerber is board certified in Internal Medicine and Medical Oncology.
Dr. Gerber is genuinely interested in Lung cancer and is highly active in his research pertaining to Lung cancer, including clinical trials. His research has generated over 130 publications that he has authored or co-authored, including articles, abstracts, book chapters, books reviews and invited manuscripts. His studies have contributed to invitations to lecture both nationally and internationally.
Dr. Gerber not only serves on a number of committees at UT Southwestern Medical Center, but he is also an active participant for the Lung Cancer Education Committee of the American Society of Clinical Oncology (ASCO) and the Career Development Committee with the International Association for the Study of Lung Cancer (IASLC). He has served on the editorial board of the Journal of Clinical Oncology. He has served on grant review committees for ASCO and the Department of Defense. Dr. Gerber holds memberships to several professional societies, and has been honored with numerous awards, including Best Doctors in Dallas, D Magazine, since 2011.
- Medical School
- Weill Cornell Graduate School of Medical Science (2000)
- UT Southwestern Medical Center (2004), Internal Medicine
- Johns Hopkins Hospital (2007), Medical Oncology
- Lung cancer, clinical and translational research
- Oncology outcomes research
- Impact of prior cancer on eligibility for lung cancer clinical trials.
- Gerber DE, Laccetti AL, Xuan L, Halm EA, Pruitt SL J. Natl. Cancer Inst. 2014 Nov 106 11
- Stromal platelet-derived growth factor receptor a (PDGFRa) provides a therapeutic target independent of tumor cell PDGFRa expression in lung cancer xenografts.
- Gerber DE, Gupta P, Dellinger MT, Toombs JE, Peyton M, Duignan I, Malaby J, Bailey T, Burns C, Brekken RA, Loizos N Mol. Cancer Ther. 2012 Nov 11 11 2473-82
- Consent timing and experience: modifiable factors that may influence interest in clinical research.
- Gerber DE, Rasco DW, Skinner CS, Dowell JE, Yan J, Sayne JR, Xie Y J Oncol Pract 2012 Mar 8 2 91-6
- How Have We Diagnosed Early-Stage Lung Cancer without Radiographic Screening? A Contemporary Single-Center Experience.
- Taiwo EO, Yorio JT, Yan J, Gerber DE PLoS ONE 2012 7 12 e52313
- Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors.
- Gerber DE, Stopeck AT, Wong L, Rosen LS, Thorpe PE, Shan JS, Ibrahim NK Clin. Cancer Res. 2011 Nov 17 21 6888-96
- Lung cancer diagnostic and treatment intervals in the United States: a health care disparity?
- Yorio JT, Xie Y, Yan J, Gerber DE J Thorac Oncol 2009 Nov 4 11 1322-30
Targeted Therapies for Non-Small Cell Lung Cancer
David E. Gerber (2011). Oxford University Press
Apar K. Ganti, David E. Gerber (Ed.) (2014). Oxford University Press
Honors & Awards
- Castle Connolly Top Doctors
- D Magazine Best Doctors in Dallas
- National Cancer Institute Clinical Investigator Team Leadership Award
- International Association for the Study of Lung Cancer (2008)
- American Society of Clinical Oncology (2004)